Back to Search Start Over

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation

Authors :
Richard Rosenquist
Eugen Tausch
Thorsten Zenz
M. Gonzalez Diaz
D. Rossi
Lesley-Ann Sutton
K. Stamatopoulos
Frederic Davi
S. Stilgenbauer
Carsten Utoft Niemann
Carol Moreno
Gianluca Gaidano
Šárka Pospíšilová
David Gonzalez
Arnon P. Kater
Jitka Malčíková
Thierry Soussi
Paolo Ghia
CCA - Cancer biology and immunology
Experimental Immunology
Clinical Haematology
AII - Amsterdam institute for Infection and Immunity
AII - Inflammatory diseases
Malcikova, J.
Tausch, E.
Rossi, D.
Sutton, L. A.
Soussi, T.
Zenz, T.
Kater, A. P.
Niemann, C. U.
Gonzalez, D.
Davi, F.
Gonzalez Diaz, M.
Moreno, C.
Gaidano, G.
Stamatopoulos, K.
Rosenquist, R.
Stilgenbauer, S.
Ghia, P.
Pospisilova, S.
Masaryk University
Universität Ulm - Ulm University [Ulm, Allemagne]
Oncology Institute of Southern Switzerland (IOSI)
Uppsala University
Karolinska Institutet [Stockholm]
Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138))
École pratique des hautes études (EPHE)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)
Cancer Center Karolinska [Karolinska Institutet] (CCK)
University hospital of Zurich [Zurich]
University of Zürich [Zürich] (UZH)
Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC)
University of Amsterdam [Amsterdam] (UvA)
Rigshospitalet [Copenhagen]
Queen's University [Belfast] (QUB)
Service d'Hématologie Clinique [CHU Pitié-Salpêtrière]
Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP]
Universidad de Salamanca
Hospital de la Santa Creu i Sant Pau
Universitat Autònoma de Barcelona [Barcelona] (UAB)
CERTH
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS San Raffaele Pisana)
Universita Vita Salute San Raffaele (UniSR)
Masaryk University [Brno] (MUNI)
École pratique des hautes études (EPHE)
Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)
Universität Zürich [Zürich] = University of Zurich (UZH)
Copenhagen University Hospital
Service d'Hématologie clinique [CHU Pitié-Salpêtrière]
CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Universitat Autònoma de Barcelona (UAB)
Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie] (UniSR)
University of Zurich
Ghia, P
Source :
"Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2018, 32 (5), pp.1070-1080. ⟨10.1038/s41375-017-0007-7⟩", Recercat: Dipósit de la Recerca de Catalunya, Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya), Malcikova, J; Tausch, E; Rossi, D; Sutton, L A; Soussi, T; Zenz, T; Kater, A P; Niemann, C U; Gonzalez, D; Davi, F; Gonzalez Diaz, M; Moreno, C; Gaidano, G; Stamatopoulos, K; Rosenquist, R; Stilgenbauer, S; Ghia, P; Pospisilova, S (2018). ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia, 32(5):1070-1080., Leukemia, Zurich Open Repository and Archive, PubMed Central, Dipòsit Digital de Documents de la UAB, Universitat Autònoma de Barcelona, Leukemia, 32, 1070-1080. Nature Publishing Group, LEUKEMIA, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname, Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2018, 32 (5), pp.1070-1080. ⟨10.1038/s41375-017-0007-7⟩, Malcikova, J, Tausch, E, Rossi, D, Sutton, L A, Soussi, T, Zenz, T, Kater, A P, Niemann, C U, Gonzalez, D, Davi, F, Gonzalez Diaz, M, Moreno, C, Gaidano, G, Stamatopoulos, K, Rosenquist, R, Stilgenbauer, S, Ghia, P, Pospisilova, S & European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) — TP53 network 2018, ' ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation ' Leukemia, vol. 32, pp. 1-11 . DOI: 10.1038/s41375-017-0007-7, Malcikova, J, Tausch, E, Rossi, D, Sutton, L A, Soussi, T, Zenz, T, Kater, A P, Niemann, C U, Gonzalez, D, Davi, F, Gonzalez Diaz, M, Moreno, C, Gaidano, G, Stamatopoulos, K, Rosenquist, R, Stilgenbauer, S, Ghia, P & Pospisilova, S 2018, ' ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-Update on methodological approaches and results interpretation ', Leukemia, vol. 32, no. 5, pp. 1070-1080 . https://doi.org/10.1038/s41375-017-0007-7, Recercat. Dipósit de la Recerca de Catalunya
Publication Year :
2018

Abstract

Altres ajuts: Supported by the IMI 2 HARMONY JU under GA No 116026, this JU receives support from the EU's H2020 R&I program and EFPIA. Further supported by the EU Horizon 2020 projects MEDGENET 692298, AEGLE 644906, projects CEITEC 2020 (LQ1601), NCMG research infrastructure (LM2015091 funded by MEYS CR), project FNBr 65269705, FM MU ROZV/24/LF/2016, DFG (SFB1074, projects B1 and B2, and EU (FIRE CLL)), and the Swedish Cancer Society and the Swedish Research Council. Publication reflects only the authors' views and the Commission is not responsible for any use that may be made of the information it contains. In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. On these grounds, analysis of TP53 aberrations has been incorporated into routine clinical diagnostics to improve patient stratification and optimize therapeutic decisions. The predictive implications of TP53 aberrations have increasing significance in the era of novel targeted therapies, i.e., inhibitors of B-cell receptor (BcR) signaling and anti-apoptotic BCL2 family members, owing to their efficacy in patients with TP53 defects. In this report, the TP53 Network of the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) presents updated recommendations on the methodological approaches for TP53 mutation analysis. Moreover, it provides guidance to ensure that the analysis is performed in a timely manner for all patients requiring treatment and that the data is interpreted and reported in a consistent, standardized, and accurate way. Since next-generation sequencing technologies are gaining prominence within diagnostic laboratories, this report also offers advice and recommendations for the interpretation of TP53 mutation data generated by this methodology.

Details

ISSN :
08876924, 65269705, and 14765551
Database :
OpenAIRE
Journal :
"Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2018, 32 (5), pp.1070-1080. ⟨10.1038/s41375-017-0007-7⟩"
Accession number :
edsair.doi.dedup.....1a82acc002fba73b8fc5a3c52bc50b9b
Full Text :
https://doi.org/10.5167/uzh-151201